Physician profile
Lynne Bui
NPI 1114169323
$16,857.34
in general payments reported to CMS, 2019-2025
63 companies · $1,461 in 2025
The $1,461 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,652 · 2020: $2,900 · 2021: $2,325 · 2022: $2,167 · 2023: $2,234 · 2024: $1,119 · 2025: $1,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,377 · Education: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,376.67 |
| Education | $437.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,360.48 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Janssen Biotech, INC. | $2,382.98 | 2019-2025 | Erleada, Akeega, Darzalex |
| Pfizer INC. | $1,159.44 | 2019-2025 | |
| Seagen INC. | $1,040.65 | 2019-2023 | Adcetris |
| Glaxosmithkline, LLC. | $926.96 | 2020-2025 | Jemperli, Ojjaara, Zejula |
| Amgen INC. | $791.82 | 2019-2023 | Xgeva, Nplate, Vectibix |
| Novartis Pharmaceuticals Corporation | $637.08 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $526.06 | 2020-2024 | Ninlaro, Iclusig |
| Lilly USA, LLC | $514.02 | 2020-2025 | Verzenio, Jaypirca, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $410.64 | 2019-2025 | Reblozyl, Opdivo |
| Exelixis INC. | $385.17 | 2019-2024 | Cabometyx |
| Daiichi Sankyo INC. | $366.99 | 2019-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $336.28 | 2019-2025 | Lynparza, Keytruda |
| Celgene Corporation | $309.90 | 2020-2025 | Reblozyl, Pomalyst |
| Progenics Pharmaceuticals, INC. | $277.29 | 2022-2025 | Pylarify |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynne Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.